Phacilitate Leaders Forum

17th - 18th SEPTEMBER 2019


Phacilitate Leaders Europe Agenda 2018


Panel discussion

12 Sep 2018
  • What is the data to illustrate the ROI from automation in terms of quality, robustness, time and FTE savings, and Cost of Goods?
  • How is it being measured? Is there any hard data yet to suggest when you should begin investing in automation, and when subsequently you could expect to see ROI?
  • Scale-up at a cost reduction: Are closed automated systems and bioreactors justifying the up-front investment?
  • How regulators views are evolving re. GMP for ATMPs and on the role of automation in cell therapy manufacture specifically? (Especially as it relates to product comparability) 


  • Have your say: panel discussion to be opened up to the audience for input after each discussion point
  • Real thinking forward combining experts in the field from manufacturing, regulatory and value vision” – “great network with strong experience and sharing risks & opportunities
    Jean-Philippe Combal
    GenSight Biologics
  • The conference consistently proves to be a great forum for networking with industry leaders in the development of cellular and gene therapies as well as vendors for important technologies and services.
    Michael Covington
    Juno Therapeutics, Inc
  • It was a very interesting event as all participants, including speakers were ready to exchange, even on the most challenging subjects such as reimbursement, GMP guidance
    Bertrand Alexandre
  • Phacilitate EU delivered it's promise and more, the topics discussed were highly relevant, with very good and professional speakers and panelists. You will see me next year in Berlin.
    Dr Ohad Karnieli
    Karnieli Ltd